Ardent Health Q2 Earnings Plunge 77% as Costs Surge and SEC Inquiry Looms
ARDT sits 43% above its 52-week low of $7.71.
Summary
Ardent Health's Q2 2026 net income plunged 77% to $16.9M as revenue dipped and costs surged, while the company disclosed an SEC inquiry into a prior revenue adjustment.
Key Events · Earnings and Guidance · ARDT
-
Net Income Plunges 77%
Net income attributable to Ardent Health fell to $16.9M in Q2 2026 from $73.0M in Q2 2025, driven by higher costs and lower supplemental payments.
-
Revenue Decline and Cost Surge
Total revenue decreased 1.4% to $1.62B, while operating expenses rose to 97.3% of revenue from 92.6% a year ago, with G&A costs nearly doubling to $61.2M.
-
Medicaid Supplemental Payment Hit
Revenue from Medicaid supplemental payment programs dropped $57.8M vs Q2 2025 due to the delayed renewal of New Mexico's program, which had boosted the prior-year quarter.
-
SEC Inquiry Disclosed
The company received an SEC letter on July 31, 2026, requesting information about a $43M revenue decrease related to accounts receivable collectability reported in November 2025.
Analysis · ARDT · Industrial Applications And Services
Ardent Health's Q2 2026 net income attributable to the company collapsed to $16.9 million from $73.0 million a year ago, a 77% drop, as revenue slipped 1.4% and operating expenses jumped 4.7% of revenue. The quarter was hit by a $57.8 million decline in Medicaid supplemental payments due to the timing of New Mexico's program renewal, while general and administrative costs nearly doubled to $61.2 million from severance and CEO transition expenses. Adding to the pressure, the company disclosed an SEC inquiry into a $43 million revenue adjustment from accounts receivable collectability. The results underscore the operational and regulatory headwinds facing the hospital operator, even as it reaffirmed full-year EBITDA guidance.
At the time of this filing, ARDT was trading at $11.06 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $7.71 to $15.48. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.